Blood concentrations of cyclosporine were determined in adult and pediatric patients foJlowing orthotopic liver transplantation to quantitate cyc10sparine blood clearance and oral absorption. Seventeen bioavailability studies were performed follOWing transplantation surgery in nine children and seven adults. The intravenous cycl08porine study was performed following an average dose of 2.1 mglkg. The patients were again studied when they received the same intravenous dose plus an oral dose of cycl08porine of 8.6 mg/kg or an oral dose alone. Blood samples were collected and analyzed for cycl08porine using high-performance liquid chromatography. Cycl08porine blood clearance ranged from 29 to 203 mUmin (1.9-21.5 mUmin/kg) in children and from 253 to 680 mVmin (3.2-7.6 mL/min/kg) in adults. The mean cyc1osporine clearance value was 9.3 mUminlkg in the pediatric patients and 5.5 mUminlkg in the adults. Cyciosporine bioovailability was less than 5% in six studies on (rve pediatric patients in the immediate postoperative period. The bioavailability varied from 8% to 60% in adult liver transplant patients [mean. 27%J. We conclude that: (1) cyclosporine clearance is highly variable between patients. (2) pediatric patients clear the drug more rapidly than adults and therefore need a higher cyclosporine dose on a body weight basis, {3} cyc1osporine is poorly and variably absorbed in liver transplant patients, and (4} cyclosporine blood concentration monitoring is essential following orthotopic liver transplantation.
O rthotopic liver transplantation is now considered a therapeutic alternative for children with diseases such as biliary atresia and alphal-antitrypsin deftciency and for adults with primary biliary cirrhosis and sclerosing cholangitis. 1 -S Therapy with cyclosporine and low-dose steroids constitutes a major advance in the treatment of patients undergoing orthotopic liver transplantation. s Liver transplantation presents special problems in maintaining adequate pharmacologic immunosuppression. The absorption, metabolism, and excretion of pharmacologic agents can be expected to be significantly altered by the transplantation procedure. Aggressive drug therapy is often needed to achieve adequate immunosuppression.
Adequate blood concentrations of cyclosporine are maintained following orthotopic liver transplantation by prolonged intravenous (IV) and combined IV and oral therapy. This cyciosporine dosing regimen is different than that used following renal or heart transplantation and prompted us to Investigate the clearance and bioavailability of cyclosporine following orthotopic liver transplantation.
PATIENTS AND METHODS
All patients who underwent orthotopic liver transplantation were considered candidates for the study. Seventeen studies were performed after patient (seven adults) or parental =t~,':nlO;Jd~)"j fr'":('~' httpJ/www.jclinphMTl_orga:.I·!I ... ~r-~!rr;:)G· .. j~(jH..tf"l ..... vli • .:. ... ~'r!flA (nine children) consent was obtained. Fifteen patients received the same intravenous cyclosporine dosage every eight hours for at least 24 hours before the start of the study.
Protocol
On the first study day. the patients received their prescribed IV cyclosporine dosage infused over two hours by Harvard infusion pump (Bard Medical Systema. North Reading. MA) or an IV drip set. In the ten pediatric studies. heparinized blood samples were obtained before the start of the infusion. at the end of the infusion. and at four. six, and eight hours following the start of the infusion. Hourly blood samples were coJIected during the dosing interval in adults. On the second study day. ten children and two· adults received the same IV dose of cyclosporine at the same time of the day. but also received an oral cycl08porine dose concurrent with the start of the infusion. Five adult patients received only oral cycJosporine q12h on the second day. The oral cyclosporine liquid was diluted with juice or cpocolate milk. ptixed. and administered as quickly as possible. The blood sampling on the second day ronowed the same schedule as that of the flrst day. with the exception that the adult patients were sampled hourly for 12 hours.
Concurrent medications administered w!th cyclosporine included methylprednisolone or prednisone. cefotaxime and ampicillin. captropril. hydralazine.· furosemide. and nystatin.
Blood samples were refrigerated at 4°C until assayed «7 days). AJ1 extraction and a high-performance liquid chromatographiC assay similar to that of Sawcquk and Cartier was used7 The assays were performed using whole blood. and cycl08porin 0 was the internal standard; The drug was initially extracted Into diethyl ~ther. After dryinS. the residue was taken up in me~nol. combined yvith hydro· chloric acid. and washed ~ce with h~ne. After neutral· ization. the drug and internal standard were reextracted into ether. dried. and reconstituted with the mobile· phase before injection. The samples were injected onto a lS-em C-18 column (Supelco. Bellefonte. PAl maintained at 70°C. The mobile phase was 68"10 acetonitrile in water with a flow rate of 1.5 mLlJnin. lTltraviolet detection was achieved at 214 nm with a Model 441 detector (Waters. Milford. MAJ. All samples and standards were analyzed in duplicate. The retention times for cyclosporine and cyclosporin D were 8.3 and 11.2 minutes, respectively. 'The minimum detectable level of this assay is 25 ng/mL using one milliliter of blood.
Standard curves were run (rom concentrations of 50-2.000 ng/mL. The Interday coefftclent of variation of the assay was 8.0"1. at 250 ng/mL (N -35). 6.4"1. at 500 ng/mL (N = 191. and 7.7% at 1,000 ng/mL [N = 23).
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Data Analysis
The short dosing interval precluded calculation of a half· life or elimination'rate constant. All studies were carried out at steady-state or pseudo-steady-state conditions. The area under the curve (AUG) for the blood concentration versus time curve was calculated by the trapezoidal rule over one dosing interval. Drug clearance was calculated as the IV cyclosporine dose divided by the A UC (IV) and bioavail. ability percentage (F) was calculated as:
Rank correlation of subgroups were compared using the Wilcoxon two-tailed analysis assuming a level of significance of P S .05.
RESULTS
The characteristics of the patients at the time of study are listed in Table 1 . Patient 7 was studied twice after two separate transplant operations. Nine of the studies were performed after the first orthotopic liver transplantation.
seven after the second. and one after the third operation. Nine of the studies were started on the second or third day postoperatively.
The maximum blood concentration after the IV cycI08PO· rine was observed at the end of the infusion and the blood concentration declined in a biexponential fashion. Figures 1  and 2 present the blood concentrauon versus time for a representative adult and pediatric:: patient. Table II lists the estimated pharmacokinetic parameters derived from the blood concentration versus time data. The average cyclosporine dosage was 2.1 mg/kg IV and 8.6 mg/kg orally. The mean trough concen~tion at eight hours was 298 ng/mL following IV cyclosporine in the pediatric patients. Four of the pediatriC patients had a cyclosporine clearance of 8l'eater than ~O mLlmin/kg. The clearance of cyclosporine in the "dull patients ranged from 3.2 to 7.6 mUmin/kg. The mean cyclosporine clearance WiS 9.3 mLlmin/kg in the pediatric population and 5.5 mL/min/kg 4t the adults.
Six studies,Gonducted in the pediatric study pOPlliation in the immeqiate postoperative period demonstrated an estimated bioavailabillty of less than 5"10 of the orally administered cyclosporine. In these patients. cyc10sp0rine clearance was less lhlln 10 mL/min/kg. The other four children with bioavailability greater than 50/. had cycloaporine blood clearances greater than 10 mLhnin/kg (p ... 01). A wide variatioJl in the' extent of absorption iii adult patients was observed as Indicated by a bioavallability of 8% to 6O"!o (mean ± standartl deviation -27 ± 18"1.). The two adults with an 8% and 15'70 bioavailability had a serum bilirubin In the present stl1dy. a tenfold variation in the clearance of cyclosporine was observed in pediatric liver fnplsplant patients. The day to day variability In clearance in an individual patient has not been assessed and may· have contributed in part to this variation. Pediatric patients had a higher harmonic lRean cyclosporine clearance per body weight as compared with adult liver transplant patients. even though they were studied earlier in their course of 649 • J CUn PtuIrmKoI 1986; 26:647~51 thctrapy. The highest cyclosporine clearance value (21.5 mLlmin/lcg) was noted in the youngest study patient (age, 7 montha). The higher cyciosporine clearance in children Is conlisten, with the oblerva~ot18 of bisber clearance per body weight of other drugs such' as theophylline in the pediatric popula~onll and with our studies of cycJosporine in pediatric lddney aod he8rt tranlplant patients. 12 Pediatric renal transplant patients ru.ve the highest cycl08porine blood clearance values. with a harmonic IJ!.lt8n clearance of 11.8 mLlmin/lcg.l1 The ~her cyc10sp0rine clearance in children il consistent with the higher drug doses on a body weight buts Uutt are ffequentIy neceslarY' to achieve blood concentrations similar to tho-. seen iii adults.
Studies in bone marrow a~d Jddney ~lant patients have shown cOnsidel'lJble variation in the peak plasma levels of cyciosporine following oral admlnistratipn of the p.rus. 1 t.15 The ~i08vailabjJity of cyc~osporin~ has been reported to ~nge from 10,., to 50,.". with a m!'aD of 34,.
•. 111 We have observed an ave~ bioavailability of 27.6". in 41 renal transplant patients in whom a mar~ed variation in the bioavailability of cycl08porine ~ also been observed (range, <5,." to 89,.,,).8 .
Because of the limitations in the study design imposed by this patient population. the bi08vailabUlty parameters calculated are only estimates of the a~l biolivailabillty values. We most likely underestim!lted bioavailability if hepatic drug c;~earance had improved on the oral ~Y day, Figure 2 . Cyclosporlne blood concentraiion vetIUI time in pediatric study poti!Inf 6. Concentrations following an inllUV!lnous (e--eJ and an introv!ll1OUll plus oral (x --xJ dose are pretenred. but may. have overestimated bioavailability if steady state had not been achieved at the titne of the intraven0U8 study.
The vehicle uaed to dilute the c:hiig Huice or milk) wiD not however affect drus abeorption. 17 Cbangea in drus clearance between the intravenous and oral study would also change the bioavailability estimate.
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In the pediatric orthotopic liver transplantation patients, cyclosporine was very poorly absorbed. The bioavailabUity ranged from <50/. to 18%. The poor absorption of cyclosporiDe in our pediatric orthotopic liver transplantation recipi. ~nts was predictable from C?ur previous clinical experience. However. we did not anticipate such a large variation in the absorption in the immedIate postoperative period. This observation indit:ates that not all orthotopic liver transplantation patients require prolonged intravenoUs therapy. The early initiation of oral eyclosporiDe in conjUnction with the intravenous formulation while monitoring trough blbOd concentrationS is an effective test of drug absorption. This regimen facilitates the early conversion from intravenous to oral therapy with cyclosporine in those patients who adequately absorb the drug.
In contrast with the poor cyclosporine absorption observed in our pediatric population in the immediate postoperative period, adults with improving liver function following orthotopic liver transplantation absorbed 8111. to 60% of an oral cyclosporine dose. Cyc10sp0rine bi08vail· ability has been reported to increase three-to fivefold over a three-month time period in renal transplant patients. 15 Improving liver function and bile flow in liver transplant recipients may be responsible for improving cyclosporioe absorption over time and may permit a dosage reduction.
Increases in the trough blood concentrations of cyclosporine are particularly notable following T-tube clamping in 
